Interpreting results from biomarker-guided clinical trials: avoiding “negative” or “failed” terminology by Nurulamin M. Noor, Haiyan Zheng, David S. Robertson, Joshua Savage, Christina Yap, Andrea L. Jorgensen, James M. S. Wason, on behalf of the MRC-NIHR Trial Methodology Research Partnership (TMRP) Precision Medicine Working Group

Get full text

Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: t... by Martin Forster, Joseph Sacco, Christina Yap, Kevin Harrington, Hisham Mehanna, Anthony Kong, James Good, Amanda Kirkham, Joshua Savage, Rhys Mant, Laura Llewellyn, Joanna Parish, Rachel Spruce, Stefano Schipani, Patrick Murray, Gary Middleton

Get full text

A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer by Gary Middleton, Helen L. Robbins, Peter Fletcher, Joshua Savage, Manita Mehmi, Yvonne Summers, Alastair Greystoke, Nicola Steele, Sanjay Popat, Pooja Jain, James Spicer, Judith Cave, Paul Shaw, David Gilligan, Danielle Power, Dean Fennell, Maya Bajracharya, David J. McBride, Uma Maheswari, Alexander M. Frankell, Charles Swanton, Andrew D. Beggs, Lucinda Billingham

Get full text